What is Immunome?
Immunome is a pioneering biopharmaceutical enterprise dedicated to transforming disease treatment through its proprietary human memory B cell platform. By isolating and analyzing the highly educated components of the immune system from patients who have successfully combated specific diseases, the company identifies novel therapeutic antibodies and their corresponding targets. This discovery engine is specifically engineered to develop first-in-class therapeutics, with an initial strategic focus on oncology and infectious diseases, including COVID-19. The company's methodology represents a paradigm shift in drug discovery, moving beyond traditional screening methods to harness the natural intelligence of the human immune system.
How much funding has Immunome raised?
Immunome has raised a total of $201.4M across 8 funding rounds:
Debt
$846K
Debt
$892K
Private Equity
$3.6M
Series A
$5M
Debt
$350K
Stock Offering
$39M
Share Placement
$27M
Share Placement
$124.7M
Debt (2010): $846K, investors not publicly disclosed
Debt (2014): $892K, investors not publicly disclosed
Private Equity (2015): $3.6M, investors not publicly disclosed
Series A (2016): $5M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Stock Issuance/Offering (2020): $39M, investors not publicly disclosed
Share Placement (2021): $27M, investors not publicly disclosed
Share Placement (2023): $124.7M, investors not publicly disclosed
Key Investors in Immunome
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
PPP
Public-Private Partnership
What's next for Immunome?
With the recent infusion of capital, Immunome is well-positioned to transition into a more mature phase of clinical development. The strategic roadmap likely involves expanding its research and development capabilities to expedite the transition of its lead candidates from the laboratory to clinical trials. As the company scales, it will likely focus on strengthening its intellectual property portfolio and forging strategic partnerships to enhance its market reach. The current funding environment suggests that Immunome is prioritizing the acceleration of its pipeline, aiming to deliver transformative treatments that address significant unmet medical needs in oncology and infectious disease management. Investors and industry observers will be closely monitoring the company's progress as it leverages this financial backing to achieve key clinical milestones.
See full Immunome company page
